Pa. cell therapy developer seeks to raise $45.1M from stock offering

09/27/2013 | American City Business Journals

Fibrocell Science, which specializes in developing autologous cell treatments, estimated it could bring in $45.1 million in a public offering of stocks expected to close next week. Proceeds will support Phase II and III trials of its azficel-T wrinkle treatment. The trials will evaluate azficel-T's efficacy in treating burn scars, acne scars and vocal cord scars.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD